Follitropin beta

Adult: In anovulatory infertile women in whom the cause of infertility is functional and not due to primary ovarian failure: Follistim AQ cartridge Initially, 50 IU daily via SC inj for at least the 1st 7 days of treatment. Increase by 25 or 50 IU at weekly intervals until follicular growth and/or estradiol levels indicate an adequate ovarian response. Puregon Initially, 50 IU daily via SC inj (as cartridge) or IM/SC inj (as vial) for at least the 1st 7 days. Increase gradually until follicular growth and/or plasma estradiol levels indicate an adequate response. Alternatively, 75-150 IU daily via SC or IM inj for 5-7 days; if there is no apparent ovarian response, the daily dose is gradually increased until estrogen levels start to rise. A daily increase of 40-100% is considered to be optimal. The daily effective dose is then maintained until pre-ovulatory conditions are reached. If estrogen levels rise too rapidly (i.e. more than a daily doubling for 2-3 consecutive days), the daily dose should be decreased. Dosage recommendations and routes of administration vary among countries or individual products. Refer to specific product guidelines.

Adult: As part of an in vitro fertilisation or intracytoplasmic sperm inj cycle and other related procedures: Follistim AQ cartridge Initially, 200 IU daily via SC inj for at least the 1st 7 days of treatment. Subsequent doses may be adjusted based on ovarian response. Dosage reduction may be considered in high responders from the 6th day of treatment onwards according to response. Puregon Initially, 100-225 IU daily via SC inj (as cartridge) or IM/SC inj (as vial) for at least the 1st 4 days of treatment. The dose may be adjusted based on ovarian response. Alternatively, 75-300 IU daily. Dosage recommendations and routes of administration vary among countries or individual products. Refer to specific product guidelines.

Adult: In men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure: Pre-treatment with hCG is required prior to concomitant therapy with follitropin beta and hCG. Follitropin beta therapy may be initiated after normal serum testosterone levels have been reached at a dose of 450 IU weekly (administered as 225 IU twice weekly or 150 IU 3 times weekly) via SC inj (as cartridge) or IM/SC inj (as vial) in combination with the same hCG dose used to normalise testosterone levels. Alternatively, 75 IU daily or 2-3 times weekly via SC or IM inj. Dosage recommendations and routes of administration vary among countries or individual products. Refer to specific product guidelines.